[A19-33] Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2019
Commission awarded on 05.04.2019 by the Federal Joint Committee (G-BA).
Immune system and infections
Chronic hepatitis C virus infection in adolescents aged 12 to < 18 years
Added benefit not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A17-34||Glecaprevir/pibrentasvir (chronic hepatitis C) – Benefit assessment according to § 35a Social Code Book V||Commission completed|
|A21-88||Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.